6505--Collegium Pharmaceutical, Inc. Effective 09/01/2026 to 08/31/2031

Where this opportunity stands

Every notice posted under solicitation 36F79726D0174 in this department, oldest first.

Next steps for this stage

Standard steps for the notice type; not advice about this buyer.

• Note the winner and the end of the period of performance for the recompete.
• Follow the agency to see the next notice for this work.

Who won similar work

77 award notices on SAM.gov in the last 24 months. Matched by: Same office (NAC FEDERAL SUPPLY SCHEDULE (36F797)), same product/service code (PSC) 6505 and NAICS 325412.

Single-winner award sizes (75): middle half $668K to $156.5M, median $23.8M; range $225K to $8.0B.

Value counts single-winner awards. "Shared" awards are multiple-award contracts that list every winner with the same total ceiling; that ceiling is not one company's win, so it is not added in. Revenue next to a ticker is the company's last annual revenue from its 10-K.

• Sep 29, 2026DECIPHERA PHARMACEUTICALS, LLC$183.8M6505--Deciphera Pharmaceuticals LLC (65IB), 36F79726D0211, Effective 09/29/2026 - 09/28/2031No listed company matched (Materiality N/A)
• Sep 25, 2026WILSHIRE PHARMACEUTICALS, INC$27.2M6505--Wilshire Pharmaceuticals, 36F79726D0208, Schedule 65 I B Effective Dates: 09/29/2026 -09/28/2031No listed company matched (Materiality N/A)
• Sep 24, 2026CYTOKINETICS, INCORPORATED$500K6505--Cytokinetics, Incorporated Effective: 09/29/2026 - 09/28/2031Materiality: 0.74% of $CYTK revenue (Low)Calculated as Award Amount divided by the company's trailing twelve-month revenue (SEC 10-Q). Here: $500K award ÷ $67.7M revenue, 12 months to Jun 30, 2026 (SEC 10-Q). SEC
• Sep 24, 202660 DEGREES PHARMACEUTICALS, INC.$475K6505--60 Degrees Pharmaceuticals, Inc. 65IB 36F79726D0212 9/29/2026 TO 9/28/2031Materiality: 42.8% of $SXTP revenue (High)Calculated as Award Amount divided by the company's trailing twelve-month revenue (SEC 10-Q). Here: $475K award ÷ $1.1M revenue, 12 months to Jun 30, 2026 (SEC 10-Q). SEC
• Sep 23, 2026GENZYME CORPORATION$670.0M6505--Genzyme CorporationNo listed company matched (Materiality N/A)
• Sep 17, 2026LANTHEUS MEDICAL IMAGING, INC.$76.0M6505--65IB: Lantheus Medical Imaging Inc. | 36F79726D0204 | Period of Performance: 09/30/2026 to 09/30/2031No listed company matched (Materiality N/A)
• Sep 17, 2026VIVUS LLC$285.7M6505--Vivus LLC, 65IB, 36F79726D0185, Performance Period: 09/29/2026 - 09/30/2031No listed company matched (Materiality N/A)
• Sep 16, 2026CHIESI USA INC$50.0M6505--Chiesi USA, Inc. 65IB, 36F79726D0203 09/30/2026-09/29/2031No listed company matched (Materiality N/A)
• Sep 14, 2026BAUSCH HEALTH US LLC$3.7BBausch Health US, LLC Award 09/30/2026 - 09/30/2031Materiality: 33.9% of $BHC revenue (High)Calculated as Award Amount divided by the company's trailing twelve-month revenue (SEC 10-Q). Here: $3.7B award ÷ $10.9B revenue, 12 months to Jun 30, 2026 (SEC 10-Q). SEC
• Aug 31, 2026LUNDBECK LLC$76.0M6505--Lundbeck LLC. 65IB 36F79726D0172 09/15/2026 - 09/14/2031No listed company matched (Materiality N/A)

Materiality: one award's value as a share of the winner's revenue over the latest 12 months in its SEC filings (or its last fiscal year, as noted when you point at it). Low under 1%, Medium 1 to 5%, High 5% or more. Many awards are paid over several years, so this overstates a single year's share.

Competitive landscape

For the 8 most frequent past winners above. Lobbying is matched by the company's exact name or exact ticker; agencies are as named on the filings.

Policy around it

Bills the past winners named while lobbying this agency's issues, rules from the department, and executive orders that name the agency, last 12 months.

Market

For past winners matched exactly to a listed company. Insider trades are open-market buys and sells (Form 4) in the last 90 days, shown as facts; our own study found insiders do not reliably buy ahead of awards. A sale marked 10b5-1 was made under a trading plan set up in advance.